Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Exelixis’ Cabozantinib Targets Particularly Sick Thyroid Cancer Patients

Nov 01 2011

• By Emily Hayes

Related Content

Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out

Jun 21 2010

AstraZeneca's Vandetanib Approval Includes REMS With Distribution Restrictions

Apr 07 2011

Exelixis' Lead-In Trial Design Evaluates Cabozantinib Disease Activity Against Multiple Cancers At 12 Weeks

Jun 06 2011

Will Exelixis’ Cabozantinib Miss The Boat In Prostate Cancer?

Nov 01 2011

Exelixis Explains Cabozantinib Thyroid Cancer Delay As Prostate Program Takes Shape

Jul 11 2011

Related Companies

Exelixis, Inc.

AstraZeneca PLC

Bristol Myers Squibb Company

Additional Topics

Clinical Trials BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window